Close Menu

NEW YORK (GenomeWeb) – Luminex announced today that it has received US Food and Drug Administration approval for its Aries Group B Streptococcus (GBS) assay for antepartum detection of GBS colonization in pregnant women.

The test runs on Luminex's real-time PCR-based sample-to-answer Aries system and is designed to detect GBS nucleic acid from 18 to 24 hour Lim broth enriched vaginal-rectal swab specimens obtained from pregnant women.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.